WO2007009462A3 - Treatment of migraine and headaches - Google Patents

Treatment of migraine and headaches Download PDF

Info

Publication number
WO2007009462A3
WO2007009462A3 PCT/DK2006/000418 DK2006000418W WO2007009462A3 WO 2007009462 A3 WO2007009462 A3 WO 2007009462A3 DK 2006000418 W DK2006000418 W DK 2006000418W WO 2007009462 A3 WO2007009462 A3 WO 2007009462A3
Authority
WO
WIPO (PCT)
Prior art keywords
channels
migraine
treatment
potassium channel
headaches
Prior art date
Application number
PCT/DK2006/000418
Other languages
French (fr)
Other versions
WO2007009462A2 (en
Inventor
Inger Jansen Olesen
Jes Olesen
Original Assignee
Koebenhavns Amt
Inger Jansen Olesen
Jes Olesen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koebenhavns Amt, Inger Jansen Olesen, Jes Olesen filed Critical Koebenhavns Amt
Publication of WO2007009462A2 publication Critical patent/WO2007009462A2/en
Publication of WO2007009462A3 publication Critical patent/WO2007009462A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Abstract

Treatment of migraine and headaches can be performed by the use of potassium channel blockers. The potassium channel blockers block KATp channels and/or BK channels. Also disclosed are the potassium channel blockers in the manufacture of a medicament for the treatment of migraine or headache. In respect of the KATP channels the potassium channel blocker may blocks channels with SUR2B subunits e.g. channels with SUR2B and Kir6.1 subunits. In respect of BKGa channels, any of the α- or β-subunits of the channels may be blocked by a potassium channel blocke in the treatment of migraine and headaches.
PCT/DK2006/000418 2005-07-15 2006-07-14 Treatment of migraine and headaches WO2007009462A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501049 2005-07-15
DKPA200501049 2005-07-15

Publications (2)

Publication Number Publication Date
WO2007009462A2 WO2007009462A2 (en) 2007-01-25
WO2007009462A3 true WO2007009462A3 (en) 2007-05-03

Family

ID=37398846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2006/000418 WO2007009462A2 (en) 2005-07-15 2006-07-14 Treatment of migraine and headaches

Country Status (1)

Country Link
WO (1) WO2007009462A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011414A (en) 2008-04-17 2011-03-15 Sanofi Aventis Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality.
EP2358750B1 (en) 2008-11-10 2017-01-11 Boehringer Ingelheim International GmbH Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
EP2632465B1 (en) * 2010-10-27 2015-12-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
DE102012022908A1 (en) 2012-11-23 2014-06-12 Itea Ecotech Gmbh Device for the use of flow energy
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
JP2022542310A (en) * 2019-07-31 2022-09-30 シー４アス－ビオテクノロジア エ レクルソス マリーニョス，エリデーアー． KV1.3 antagonists for use in treating chronic and acute pain
CN115477650A (en) * 2021-06-16 2022-12-16 中国科学院上海药物研究所 Isoquinoline alkaloid compound and preparation method and application thereof
CN116850197A (en) * 2023-07-24 2023-10-10 东北林业大学 New use of muscarinic penicillin

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007181A (en) * 1974-02-11 1977-02-08 The Upjohn Company Adamantyl containing guanidines
WO1995005815A1 (en) * 1993-08-27 1995-03-02 Janssen Pharmaceutica N.V. Iontophoretic delivery of an antimigraine drug
WO1995028377A1 (en) * 1994-04-18 1995-10-26 Abbott Laboratories Guanidine compounds as regulators of nitric oxide synthase
US5637623A (en) * 1991-02-08 1997-06-10 Cambridge Neuroscience, Inc. Substituted adamantyl guanidines and methods of use there of
WO1998019674A2 (en) * 1996-11-05 1998-05-14 Head Explorer Aps A method for treating tension-type headache
WO1999003861A1 (en) * 1997-07-16 1999-01-28 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6251948B1 (en) * 1990-03-02 2001-06-26 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US6265441B1 (en) * 1994-05-11 2001-07-24 Jes Olesen Use of no scavengers, inhibitors of antagonists in the treatment of migraine
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
WO2002000217A1 (en) * 2000-06-29 2002-01-03 Neurosearch A/S Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007181A (en) * 1974-02-11 1977-02-08 The Upjohn Company Adamantyl containing guanidines
US6251948B1 (en) * 1990-03-02 2001-06-26 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5637623A (en) * 1991-02-08 1997-06-10 Cambridge Neuroscience, Inc. Substituted adamantyl guanidines and methods of use there of
WO1995005815A1 (en) * 1993-08-27 1995-03-02 Janssen Pharmaceutica N.V. Iontophoretic delivery of an antimigraine drug
WO1995028377A1 (en) * 1994-04-18 1995-10-26 Abbott Laboratories Guanidine compounds as regulators of nitric oxide synthase
US6265441B1 (en) * 1994-05-11 2001-07-24 Jes Olesen Use of no scavengers, inhibitors of antagonists in the treatment of migraine
WO1998019674A2 (en) * 1996-11-05 1998-05-14 Head Explorer Aps A method for treating tension-type headache
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
WO1999003861A1 (en) * 1997-07-16 1999-01-28 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO2002000217A1 (en) * 2000-06-29 2002-01-03 Neurosearch A/S Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CLARK A G ET AL: "Therapeutic potential of potassium channel modulators for CNS disorders", EXPERT OPINION ON THERAPEUTIC PATENTS 01 JAN 2003 UNITED KINGDOM, vol. 13, no. 1, 1 January 2003 (2003-01-01), pages 23 - 32, XP002413534, ISSN: 1354-3776 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1980, HUNT, RICHARD H. ET AL: "Gastric secretory studies in humans with impromidine (SK&F 92676) - a specific histamine H2 receptor agonist", XP002414226, retrieved from STN Database accession no. 1980:191429 *
GASTROENTEROLOGY , 78(3), 505-11 CODEN: GASTAB; ISSN: 0016-5085, 1980 *
GOZALOV A ET AL: "Role of KATP channels in the regulation of rat dura and pia artery diameter.", CEPHALALGIA : AN INTERNATIONAL JOURNAL OF HEADACHE. APR 2005, vol. 25, no. 4, April 2005 (2005-04-01), pages 249 - 260, XP007901475, ISSN: 0333-1024 *
KHAN SAJIDA A ET AL: "Pharmacological characterization of novel cyanoguanidines as vascular KATP channel blockers", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 283, no. 3, December 1997 (1997-12-01), pages 1207 - 1213, XP007901522, ISSN: 0022-3565 *
KOVALEV H ET AL: "Molecular analysis of the subtype-selective inhibition of cloned KATP channels by PNU-37883A", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 141, no. 5, 2004, pages 867 - 873, XP007901478, ISSN: 0007-1188 *
LAWSON K: "Is there a role for potassium channel openers in neuronal ion channel disorders?", EXPERT OPINION ON INVESTIGATIONAL DRUGS. OCT 2000, vol. 9, no. 10, October 2000 (2000-10-01), pages 2269 - 2280, XP002413533, ISSN: 1354-3784 *
PERRICONE S C ET AL: "SYNTHESIS AND DIURETIC ACTIVITY OF ALKYL- AND ARYLGUANIDINE ANALOGSOF N,N'-DICYCLOHEXYL-4-MORPHOLINECARBOXAMIDINE IN RATS AND DOGS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 22, 1994, pages 3693 - 3700, XP001061691, ISSN: 0022-2623 *
PIROTTE B ET AL: "New insights into the development of ATP-sensitive potassium channel openers", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 15, no. 5, 2005, pages 497 - 504, XP002396262, ISSN: 1354-3776 *
PROUS, J. R. ET AL: "546C88: Nitric oxide synthase inhibitor; treatment for septic shock, antimigraine", DRUGS OF THE FUTURE , 23(2), 123-132 CODEN: DRFUD4; ISSN: 0377-8282, 1998, XP002414219 *
YI CUI ET AL: "Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 139, no. 1, 2003, pages 122 - 128, XP007901476, ISSN: 0007-1188 *

Also Published As

Publication number Publication date
WO2007009462A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2007009462A3 (en) Treatment of migraine and headaches
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
WO2007019439A3 (en) Block copolymer compositions and uses thereof
WO2007011739A3 (en) Polymers with low band gaps and high charge mobility
WO2007011741A3 (en) Stable organic devices
EP1715366B8 (en) Optical package, optical lens and backlight assembly having the same
WO2007067315A3 (en) Ion sources, systems and methods
WO2008054676A3 (en) Medical devices and methods of using the same
WO2006105403A3 (en) Treatment of eye disorders with sirtuin modulators
AU2006282042A8 (en) Nanoparticle fabrication methods, systems, and materials
WO2006127987A3 (en) Treatment of eye disorders with sirtuin modulators
WO2006118862A3 (en) Methods for protecting glass
WO2007076370A3 (en) Block copolymer particles
WO2006034035A3 (en) Treatment of ischemia
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2007076159A3 (en) Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
WO2005107461A8 (en) Modulating lymphatic function
WO2007112279A3 (en) Resonators
WO2006113417A3 (en) Methods and apparatuses for sealing ophthalmic lens packages
SG136926A1 (en) Package mold combination
AU2003266516A1 (en) Resin compositions, composites made by using the same, and process for production thereof
TW200636313A (en) Micro-optical device and method of making same
EP1893378A4 (en) Cutting segment, method for manufacturing cutting segment, and cutting tool comprising the same
EP1878836A4 (en) Wheel-type working machine and method of controlling the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06753355

Country of ref document: EP

Kind code of ref document: A2